Introduction {#s1}
============

The hallmark of the humoral adaptive immune response is the production of high affinity class-switched antibodies from relatively low-affinity IgM^+^ naive precursors. Affinity maturation and class switch recombination (CSR) are tightly regulated, molecular processes that occur in a specialized microenvironment within secondary lymphoid organs known as the germinal center (GC). Upon T-dependent antigen stimulation, IgM^+^ naive B cells re-localize into the B cell follicle, undergo clonal expansion within the GC. The GC reaction is an iterative process of mutation-selection that leads to the generation of antigen-specific high affinity, class-switched memory B cells and long-lived antibody secreting plasma cells \[reviewed in ([@B1])\]. Antibody class switching from IgM to IgG, IgA or IgE allows effector function diversification. Both memory B cells and long-lived plasma cells are critical determinants of vaccine efficacy ([@B2]).

CSR involves a deletion of a genomic segment from the *IGHM/IGHD* coding interval (C~μ~-C~δ~) to the upstream flank of one of the *IGHG, IGHA*, or *IGHE* genes in the telomeric region of human chromosome 14. Activated GC B cells upregulate the Activation Induced Cytidine Deaminase (AID), which deaminates cytidines in the G-rich Switch (S) regions located upstream of each immunoglobulin constant coding gene (C~H~). Cytidine deamination induces DNA damage response, which eventually leads to double stranded DNA breaks in both donor (S~μ~) and the corresponding acceptor S region. The chromosomal ends are rejoined and the C~μ~-C~δ~-encoding intervening DNA segment is re-circularized in a non-replicating episome by non-homologous end joining \[reviewed in ([@B3])\].

The initiation of CSR depends on non-coding transcription of I~H~ exons, known as germline or "sterile" transcripts (referred hereafter as CSRnc transcription). I~H~ exons are located in the 5′ region of each S-C~H~ gene module. Non-coding transcription of I~H~ exons extends to the S and C~H~ region, is coupled to chromatin remodeling and is dependent on splicing ([@B4], [@B5]). CSRnc transcripts form an R-loop in the corresponding S region, which recruits AID to target S region deamination and CSR \[reviewed in ([@B6])\]. The precise mechanism of AID targeting to the S~H~ region remains elusive, and off-target AID activity is implicated in the genesis of B cell malignancies ([@B6], [@B7]).

CSR is a complex cellular process that occurs in specialized microenvironments in secondary and tertiary lymphoid organs. The cellular choice of which I~H~ to transcribe, and consequently the Ig class to switch to, is influenced by the availability of certain cytokines such as IL-4, IFNγ, TGFβ, and PAMP\'s, among others. Such environmental cues are thought to trigger specific signals that promote selective transcription of a given I~H~ exon, guiding CSR according to a particular microenvironment or pathogenic insult ([@B3]). CSRnc transcription patterns may reflect distinctive immunological events, such as the dependence of T cell help and other micro-environmental signals. Thus, CSRnc transcription quantitation during normal and pathological human immune responses could uncover novel pathogenic mechanisms and transcriptional signatures with potential clinical value. In addition, despite CSRnc transcription is biologically linked to B cells, its expression in other cell types has not been ruled out.

The recent explosion in the generation of public genomic data, and in particular transcriptome-wide profiling with RNA sequencing (RNA-seq) provides a unique opportunity to explore previously unannotated features in the human genome. To characterize CSRnc transcription in normal and pathological conditions, we tested CSRnc transcription in human vaccination and analyzed the transcriptional landscape of the human IgH locus using more than 70,000 publicly available human RNA-seq samples from a wide variety of research projects, including the Genotype Tissue Expression project (GTEx) ([@B8], [@B9]), The Cancer Genome Atlas (TCGA) ([@B10], [@B11]), and more than 2,000 projects from the Sequence Read Archive (SRA) using *recount2* ([@B12]).

Materials and methods {#s2}
=====================

Vaccination of human healthy volunteers
---------------------------------------

Pre-immune (day 0), day 7, 15, 30, and 180 post-vaccination peripheral blood samples (18 mL) were obtained by venipuncture in 2 × 8 mL Vacutainer® CPT™ tubes from healthy volunteers vaccinated with Hepatitis B and/or Tetanus toxoid/Diphteria (*n* = 16), or Trivalent Influenza Vaccine during season 2013--2014 \[A/California/7/2009 (H1N1) pdm09; A(H3N2) A/Victoria/361/2011; B/Massachusetts/ 2/2012\] (*n* = 18). Written informed consent was obtained from each volunteer in each blood sample draw. All procedures in human subjects were performed after Institutional Review Board approval from the National Institute of Public Health (CI: 971/82-6684). Plasma and PBMCs were isolated according to the manufacturer\'s instructions, aliquoted and stored at −80°C and liquid N~2~, respectively. Total RNA was extracted from PBMCs with TRIzol and stored at −80°C until used.

Quantitation of plasmablasts by FACS
------------------------------------

Cryopreserved PBMCs were thawed at 37°C and resuspended in RPMI 10% FBS, washed with PBS 1X and fixed with 1% paraformaldehyde for 20 min at room temperature. After washed with FACS solution (PBS 1%, sodium azide 0.05% and 2% FBS), cells were incubated for 30 min at 4°C with the following antibody cocktail: anti-CD3 PerCP/Cy5.5 (clone SKY; Biolegend; 344808), anti-CD19 FITC (clone HIB19; Biolegend; 302206), anti-CD20 PE Cy7 (clone 2H7; Biolegend; 302312), anti-CD27 APC (clone O323; Biolegend;356410), and anti-CD38 PE (clone HIT2; Biolegend; 980302). Flow cytometry analysis was performed in a FACS Aria II (BD Biosciences, San Jose, CA, USA). Doublets and CD3+ events were gated out. Plasmablasts were defined as CD3^−^/CD19^+^/CD20^−^/CD27+/CD38^+^. 500-1000 plasmablasts were acquired per sample. Analysis was performed using Flowjo software (TreeStar).

B cell *in vitro* stimulation
-----------------------------

PBMCs were isolated by Ficoll-Paque™ density gradient from blood bank buffy coats. B cells were enriched through negative selection using B cell Isolation Kit II (MACS, Miltenyi). 1 × 10^6^ B cells were seeded per well on 6-well plate incubated in RPMI medium supplemented with 10% FBS, streptomycin and penicillin at 37°C with 5% CO~2~. Two activation conditions were stablished at different time points (3 and 6 days post-activation: Germinal center-like activation (GC-like), 1 μg/ml anti-human CD40 (G28.5), 5 μg/ml CpG ODN 2006 (Invivogen) and 25 ng/ml recombinant IL-21 (eBiosciences). For T-independent activation, 5 μg/ml CpG ODN 2006 (Invivogen), 0.05% *S. aureus* Cowan (Pansorbin; Calbiochem), 5 ng/ml Pokeweed Mitogen (Sigma).

qRT-PCR of CSRnc transcripts
----------------------------

Total RNA from PBMCs was extracted using TRIzol (Invitrogen). The integrity of the RNA was measured with Agilent RNA 6000 Nano. SuperScript™ III One-Step RT-PCR(Invitrogen) was used for reverse transcription and amplification. Quantitative PCR of CSRnc transcripts for *IGHM, IGHG*1, *IGHG*3, and AID gene was performed using specific primers and TaqMan probes(IDT). The primers and probes used to quantify the CSRnc transcripts are detailed in Table [1](#T1){ref-type="table"}. Amplification of *HPRT* with PrimeTime® Predesigned qPCR Assays was performed as the reference gene. The fold difference was calculated using 2^ΔΔCT^, using resting enriched B cells as calibrator and non-B cells as negative control. *HPRT* was used as normalizer for every condition.

###### 

Oligonucleotides used for qRT-PCR of Iμ, Iγ~3~, and Iγ~1~.

          **Forward**             **Reverse**              **Probe**
  ------- ----------------------- ------------------------ -------------------------------------
  Iγ~1~   CAAGCCCCTCCGTTCAC       ACGAGGAACATGACTGGATG     5-F/AGGAGGCAG/Z/CAGAGCGAGG/3IB
  Iγ~3~   CCTGTTGTGGCGAGGTACA     TTAGTGTTTGCAGCGTGGAG     5-F/CTGTCAGCT/Z/GCCACTTGTCTTCCT/3IB
  Iμ      CCAGGTGTTGTTTTGCTCAGT   CACTTCTGGTTGTGAAGAGGTG   UPL_ROCHE\#61
  AID     TGGACACCACTATGGACAGC    GCGGACATTTTTGAATTGGT     UPL_ROCHE\#69

*F, FAM; Z, ZEN; IB, Iowa Black*.

CSRnc transcription boundaries definition
-----------------------------------------

Currently, CSRnc transcripts and switch regions (S) are not mapped as such in the current version of the human genome (GRCh38). I~H~ are upstream of the corresponding switch region (S~H~), thus we first mapped S regions based on the frequency distribution of the AGCT motif in 500 bp bins along the whole *IGH* locus (105,583,700−105,863,000) ([@B3]). *recount2* is an online resource consisting of normalized RNA-seq gene and exon counts, as well as, coverage *BigWig* files (<https://jhubiostatistics.shinyapps.io/recount/>) that can be programmatically accessed through the R programming language ([@B13]). To map I~H~, metadata from all SRA projects contained in *recount2*, as well as, through the SRA-Run selector engine were used to identify RNA-seq samples and samples performed using purified B cells. The corresponding *BigWig* files were downloaded using the *recount* Bioconductor package and mapped read counts were visually inspected with Integrative Genomics Viewer ([@B14]). CSRnc regions were delimited according to an expression consensus from projects described in Table [S1](#SM2){ref-type="supplementary-material"}.

CSRnc and IGH transcription quantitation
----------------------------------------

*recount2* was used to extract read counts from each of the nine C~H~ constant region coding genes (*IGHM, IGHD, IGHG*3, *IGHG*1, *IGHA*1, *IGHG*2, *IGHG*4, *IGHE*, and *IGHA*2), as well as, from the corresponding CSRnc I exon coordinates as a *GRanges* object ([@B15]). The log~2~-transformed C~H~ (coding) and CSRnc RPKM average per *sample* was used as an approximation of abundance of transcription. For CSRnc transcription, log~2~ RPKM per *sample* average adopted a quasi-normal distribution with a mean of 2.65 log~2~ RPKM (SD ± 3.79), which corresponds to 6.29 RPKM. As an initial exploration to which tissues and in which diseases CSRnc transcription takes place, we used the log~2~ RPKM average as a cut-off to define "high" expression (\>2.65 log~2~ RPKM) or "low" expression (\< 2.65 log~2~ RPKM). The mean C~H~ transcription average log~2~ RPKM was 7.82 (SD ± 5.16). Given the difference between coding and CSRnc transcription, and to address the relative expression between coding and CSRnc transcription for each Ig loci, coding and CSRnc log~2~RPKM values for each Ig gene were standardized by transformation to Z-scores.

SRA RNA-seq samples ontology mapping
------------------------------------

Although all RNA-seq samples in TCGA and GTEx follow a homogeneous ontology categorization, metadata associated to SRA projects is widely heterogeneous and commonly insufficient. To obtain a more homogenous categorization of nearly half of our dataset, we used disease ([@B16]) annotations retrieved from MetaSRA, version 1--2 ([@B17]).

Enrichment test
---------------

To define CSRnc transcription profile variation in healthy tissue (GTEx dataset), we performed tissue sample enrichment analysis according to Z-cluster using a two sided Fisher\'s Exact Test. The H~0~ is that there is no difference in the probability distribution between Z clusters and tissue. A 2 × 2 contingency table was built for each tissue between the number of samples belonging to a given Z cluster and the remaining samples not belonging to that cluster. A two-sided Fisher\'s test was performed with the R function fisher test (c, alternative = "two.sided"). *P*-value adjustment with the Benjamini-Hochberg method was performed to correct for multiple testing using the R function p. adjust \[p, method = "bh", *n* = length(p)\]. A False Discovery Rate (FDR) \< 0.01 was considered as a significant enrichment.

CSRnc transcription profile clustering
--------------------------------------

To define CSRnc transcription profiles, Z-scores for each I-exon were subjected to *k*-means clustering using the Cluster software 3.0 ([@B18]). Ten clusters were generated, with 100 iterative runs and Euclidean distance as distance metric. Clustered data was visualized with java Treeview 3.0 (<https://sourceforge.net/projects/jtreeview/>).

Differential expression analysis
--------------------------------

Differential expression of coding IGH and CSRnc transcripts was analyzed using the functions lmFit() and eBayes() from the *limma* R package v3.34 ([@B19]). If technical replicates were present for a given study, the induced correlation was adjusted for using the duplicationCorrelation() function from *limma*. The resulting Bonferroni-adjusted *p* \< 0.05 were determined to be statistically significant. We used Bonferroni instead of FDR given that we tested 10 regions instead of the usual number of thousands of genes.

Results {#s3}
=======

CSRnc transcription is B cell-specific and its boundaries are diffuse
---------------------------------------------------------------------

Overall, *recount2* ([@B12]) comprises a highly heterogeneous catalog of RNA-seq experiments belonging to 2,036 independent studies and comprising 70,603 samples. Each study is composed of an average of 34 samples. However, TCGA ([@B10], [@B11]) and GTEx (SRP012682) ([@B8], [@B9]) are two projects (studies) with the largest number of sequencing samples (11,284 and 9,661 respectively), and represent 29% of our dataset (Figure [S1](#SM1){ref-type="supplementary-material"}).

A schematic representation of the IgH locus is shown in Figure [1A](#F1){ref-type="fig"}. Although human CSRnc transcription has been evaluated by RT-PCR ([@B5], [@B25], [@B26]), the precise transcription boundaries, including alternate transcription initiation sites and splicing variants remain undefined. We selected RNA-seq samples derived from normal FACSorted B cells to map CSRnc transcription and to define transcriptional boundaries for read count quantitation for further analysis (Table [S1](#SM2){ref-type="supplementary-material"}) ([@B27]--[@B33]). We found that in normal adult B cells, CSRnc boundaries are less sharply defined than coding transcripts, and as expected, extend into switch regions (Figure [1B--D](#F1){ref-type="fig"}) ([@B5]). Projects SRP045500 ([@B29]) and SRP051688 ([@B31]) describing the transcriptome of isolated peripheral blood (PB) immune cells in healthy adults, including primary neutrophils, monocytes, myeloid dendritic cells, B, NK and T cells revealed that among terminally differentiated hematopoietic lineage-derived cells, CSRnc transcription is restricted to B cells (Figure [1B](#F1){ref-type="fig"}, Figure [S2](#SM1){ref-type="supplementary-material"}).

![CSRnc transcription boundaries definition. Selected projects using isolated B cells were used to define the limits of CSRnc transcription in human chromosome 14 (See Table [S1](#SM2){ref-type="supplementary-material"}). **(A)** Schematic representation (not on scale) of the IgH locus in a VDJ rearranged B cell, including i-exons (I~H~, CSRnc transcripts), switch regions (S~H~, horizontal rectangles), and coding exons of the constant region (C~H~, large rectangles). The telomeric region is toward the left. *BigWig* files were downloaded using *recount2* and visualized using IGV ([@B18]) to inspect to determine the boundaries for each CSRnc transcript. **(B)** Coverage graph of project SRP045500 showing the CRIP1 locus (*left panel*) and the *IGHM* locus (*right panel*) in B (*red track*) and non-B cells. The *CRIP1* gene is transcribed in B and non-B cells, whereas *IGHM* and I~μ~ (within black vertical lines) is transcribed only in B cells and in peripheral blood (*Black track*). Predicted S~μ~ region is shown in the bottom track (*blue*) and annotated genes (GENCODE v24) are shown in *green*. **(C)** A view of the *IGHM*---*IGHD* intron locus displaying coverage graphs from normal purified naive tonsillar (SRP021509, blue track) and peripheral blood CD19^+^ B cells (SRP060715, red track). The vertical black arrow shows I~δ~. *IGHD* annotation GENCODE v24 is shown in *green*. The I~δ~ exon overlaps with the Σμ region ([@B20], [@B21], [@B22]) and is centromeric regarding the mapped sites for μ--δ CSR junctions (Dotted black arrows) ([@B21]). Antisense primer (18156) used by Kluin et al. ([@B21]) and Arpin et al. (P4) ([@B22]) are shown in purple and green, respectively. The S~δ~ Sense primer used by Chen et al. ([@B23]) is shown in orange. The *blue asterisks* indicate *Hind* III sites ([@B20], [@B24], [@B21]). **(D)** Transcriptional landscape of the *IGHA1* locus displaying coverage graphs of the *IGHA1*, GENCODE v24 annotation (*green track*), tonsillar naive (SRR834982, blue), and peripheral blood B cells (SRR2097501, red). Both I~α1.1~ and I~α1.2~ transcripts are shown. The S~α1~ region (*black bar*) is shown. For **B--D**, coverage scale is shown in the left upper corner within brackets.](fimmu-09-02679-g0001){#F1}

We analyzed CSRnc and C~H~ coding transcription in isolated PB CD19^+^ B cells. High relative transcription of I~μ~ and C~μ~, intermediate relative transcription of I~δ~, I~γ3~, I~γ1~, I~α1.2~, I~γ2~, I~γ4~ and I~α2~, and low transcription of I~ε~ and I~α1.1~ were characteristic of PB B cells (Figure [2](#F2){ref-type="fig"}) ([@B28], [@B29]). Furthermore, we analyzed CSRnc transcription in tonsillar naive and germinal center B cells from project SRP021509 ([@B27]). CSRnc transcription for most I~H~ but not I~ε~, was relatively high in both naive and GC B cells (Figure [2D](#F2){ref-type="fig"}). These findings indicate that CSRnc transcription is not exclusive of activated B cells, and agrees with previous findings demonstrating constitutive CSRnc transcription ([@B5], [@B26]).

![CSRnc transcription pattern in whole blood is similar to peripheral blood sorted CD19^+^ B cells. Relative CSRnc and C~H~ transcription (Z- score) in whole blood RNA from the GTEx dataset is shown as a 2-D contour plot (*n* = 456 samples) in **(A--C)**. Filled colored circles correspond to Z-scores of peripheral blood sorted CD19^+^ B cells derived from three independent RNA-seq projects ([@B28], [@B29]), overlaid to the GTEx data (Table [S1](#SM2){ref-type="supplementary-material"}). **(D)** 2-D density data of sorted CD19^+^ peripheral blood B cells Z-values of the projects shown in A--C (*n* = 14), overlaid with the corresponding Z scores of sorted tonsillar naïve B cells (squares. *n* = 4) and tonsillar germinal center B cells (triangles. *n* = 4) from project SRP021509 ([@B27]).](fimmu-09-02679-g0002){#F2}

A transcriptionally active 309 base-pair (bp) region within the *IGHM*-*IGHD* intron was identified (referred hereafter as I~δ~) and was included for further analysis (Figure [1C](#F1){ref-type="fig"}). This region is homologous to I~μ~, overlaps with a previously described repeat termed Σμ, implicated in μ-δ CSR in IgD^+^ myelomas ([@B20], [@B24]). For the *IGHA1* gene, we identified two potential I~H~ exons (I~α1.1~ and I~α1.2~) that were selected for downstream analysis (Figure [1D](#F1){ref-type="fig"}). I~γ2~ overlapped with a previously annotated lincRNA, ENST00000497397.1 (AL928742.1) at ENSEMBL ([@B34]). The genome coordinates of each I~H~ exon identified and further analyzed are in Table [2](#T2){ref-type="table"}. Navigation across the IgH locus using the ENSEMBL Genome Browser ([@B34]) allowed to confirm that the predicted I~H~ exons include regions of RNApolII, H3K36, and H3K4 trimethylation enrichment in peripheral blood B cells and EBV-transformed B cells generated by the Roadmap Epigenomics and ENCODE projects ([@B35], [@B36]), indicating active transcription (Figure [S3](#SM1){ref-type="supplementary-material"}). Overall, these results agree with the current model of CSRnc transcription ([@B5]); however, the identification of novel transcribed elements ads complexity to the transcriptional regulation of the IgH locus.

###### 

Mapping I exons (I~H~) and switch regions (S) in human chromosome 14.GRCh38.p10.

  **Gene**          **Start**     **End**       **Length (bp)**
  ----------------- ------------- ------------- -----------------
  ***IGHM***                                    
  Iμ                105,861,311   105,862,213   903
  Sμ                105,856,501   105,860,500   4,000
  ***IGHD***                                    
  Iδ                105,847,549   105,847,857   309
  ***IGHG*****3**                               
  Iγ~3~             105,775,023   105,775,702   680
  Sγ~3~             105,773,001   105,774,000   1,000
  ***IGHG*****1**                               
  Iγ~1~             105,747,322   105,748,299   978
  Sγ~1~             105,744,501   105,745,500   1,000
  ***IGHA*****1**                               
  Iα~1.2~           105,711,304   105,711,907   604
  Iα~1.1~           105,712,639   105,712,892   254
  Sα1               105,709,501   105,712,500   3,000
  ***IGHG*****2**                               
  Iγ~2~             105,647,803   105,648,549   747
  Sγ~2~             105,627,501   105,628,500   1,000
  ***IGHG*****4**                               
  Iγ~4~             105,629,000   105,629,500   501
  Sγ~4~             105,623,001   105,624,000   1,000
  ***IGHE***                                    
  Iε                105,605,036   105,605,357   322
  Sε                105,602,501   105,604,500   2,000
  ***IGHA*****2**                               
  Iα~2~             105,589,300   105,590,300   1,001
  Sα~2~             105,589,001   105,591,500   2,500

CSRnc transcription in peripheral blood is modified upon vaccination and does not depend on circulating plasmablasts
--------------------------------------------------------------------------------------------------------------------

CSRnc transcription increases upon B cell activation ([@B5]). To validate that, the predicted CSRnc transcripts are induced upon activation, normal human B cells were stimulated with agents mimicking T-dependent activation (CD40 ligand, IL-21 and CpG) and T independent activation (CpG, Pokeweed mitogen and SAC) *in vitro* for 3 and 6 days. We obtained whole blood total RNA and quantified I~μ~, I~γ3~, and I~γ1~ CSRnc and AID transcripts by qRT-PCR (Figure [3A--D](#F3){ref-type="fig"}). CSRnc transcripts were detected in B cells activated by both T-dependent and T-independent activators, but transcription levels were significantly higher for T-dependent like activation. In both types of activation, CSRnc transcription at 6 days post-activation was higher than 3 days post-activation (Figure [3A-D](#F3){ref-type="fig"}). The highest transcription was for I~μ~ (3-fold higher than I~γ1~ and I~γ3~). Transcription of AID showed the same pattern as CSRnc transcripts (Figure [3D](#F3){ref-type="fig"}).

![CSRnc transcripts quantitation *in vitro* and in vaccination. A qPCR Taq-Man assay for I~μ~, I~γ3~ I~γ1~, and AID was used to quantitate CSRnc transcription with the 2^ΔΔ*Ct*^ method (log~2~). **(A--D)** Enriched B cells cultured for 3 and 6 days with T-dependent like activation (**TD**) (IL-21, α-CD40) and T-independent activation (**TI**) (PWM, SAC). Bar plots represent the mean fold-change (non-activated enriched B cells /activated B cells) of two independent experiments. Non-B cells were used as control. **(E--H)** qPCR Taq-Man assay for I~μ~, I~γ3~ I~γ1~, and AID from total RNA obtained from donors\' PBMCs taken at pre-immunization (day 0) against Hepatitis B and/or Tetanus-Diphteria and on days 7 and 14 post-immunization. (Wilcoxon test. *p* \< 0.05). **(I)** Plasmablast (CD3^−^CD19^+^CD20^−^CD27^+^CD38^+^) mobilization in peripheral blood expressed as a percentage of CD19^+^ B cells (Wilcoxon test. *p* = 0.005). **(J)** Positive correlation between day 0/7 plasmablast ratio and day 0/7 I~μ~ ratio (LTS regression method. Adjusted *R*^2^: 0.53, *p*-value: 0.015). **(K)** Negative correlation between day 0/7 plasmablast ratio and day 0/14 I~γ3~ ratio (LTS regression method. Adjusted *R*^2^ = 0.63, *p*-value: 0.011). **(L--O)** No significant changes in CSRnc transcription assessed by qPCR were observed 7 and 14 days after trivalent inactivated Influenza vaccination (Wilcoxon test. *P* \> 0.05). **(L)** I~μ~, **(M)** I~γ3~, **(N)** I~γ1~, and **(O)** AID. Dotted red line indicates no change in expression (Fold-change = 1.0).](fimmu-09-02679-g0003){#F3}

Immunization promotes an antigen-specific mobilization of plasmablasts to peripheral blood around day 7 post-challenge ([@B37], [@B38]). It is likely that this plasmablast wave derives from germinal centers ([@B39]). Thus, we hypothesized that the level of CSRnc transcription in peripheral blood correlates with the amount of plasmablasts. We assessed CSRnc transcription and plasmablast proportion in peripheral blood of healthy subjects before, 7 and 14 days post vaccination with either hepatitis B (HB) alone or in combination with tetanus/diphtheria vaccine (TT/Dp) (Figure [3E--K](#F3){ref-type="fig"}). Regarding pre-immune levels, I~μ~ transcription was not affected at day 7 (mean 0.95 ± 0.5, *p* = 0.76) or at day 14 (mean 2.04 ± 2, *p* = 0.073), however at day 14 was higher than at day 7 (*p* = 0.01) (Figure [3E](#F3){ref-type="fig"}). I~γ1~ transcription was neither affected at day 7 (mean 2.9 ± 3.2, *p* = 0.057) nor at day 14 (mean 1.02 ± 0.9. *p* = 0.57) (Figure [3F](#F3){ref-type="fig"}). Contrastingly, I~γ3~ transcription regarding pre-immune levels was reduced at day 7 (mean 0.76 ± 0.3, *p* = 0.016) and increased at day 14 (mean 1.73 ± 1.1, *p* = 0.021). As expected, I~γ3~ transcription at day 14 was higher than at day 7 (*p* = 0.0002) (Figure [3G](#F3){ref-type="fig"}). No changes were detected in AID expression (Figure [3H](#F3){ref-type="fig"}).

Plasmablast levels peaked at day 7 post-vaccination (*p* = 0.011), and returned to pre-vaccine levels 14 days post-vaccination, as previously described ([@B37], [@B38]). There was no correlation between plasmablasts and I~γ1~ transcription increase at day 7 (LTS method. Adjusted *R*^2^ = −0.1265, F-statistic: 0.1013 on 1 and 7 DF, *p* = 0.75). However, plasmablast and I~μ~ transcription correlated at day 7 (Figure [3J)](#F3){ref-type="fig"} (LTS method. Adjusted *R*^2^ = 0.53; F-statistic = 10.17 on 1 and 7 DF, *p* = 0.015). Interestingly, plasmablast fold-change at day 7 negatively correlated with I~γ3~ transcription (Figure [3K)](#F3){ref-type="fig"} (LTS method. Adjusted *R*^2^ = 0.63; F-statistic = 13.04 on 1 and 6 DF, *p*-value: 0.011). No changes in I~μ~, I~γ1~, and I~γ3~ transcription was detected in response to influenza vaccination (Figures [3L--O](#F3){ref-type="fig"}). Overall, these results suggest that an increase in CSRnc transcription in peripheral blood upon vaccination is dependent on vaccine type, and that the contribution of vaccine-mobilized plasmablasts to CSRnc transcription is negligible.

CSRnc transcription is prevalent in a large fraction of the *recount2* dataset, with predominant transcription of i~μ~
----------------------------------------------------------------------------------------------------------------------

Normalized counts (RPKM) obtained with *recount2* were used to assess CSRnc transcription in the SRA, TCGA and GTEx datasets. We found no CSRnc transcription (RPKM = 0) in any of the 10 I~H~ exons in a substantial fraction of the whole dataset (*n* = 26,512 samples; 37%) (Table [3](#T3){ref-type="table"}). The I~H~ log~2~-transformed RPKM average (2.65) for each non-zero RPKM sample (*n* = 44,091; 62.4%) was used to define an expression cutoff. "High" CSRnc transcription was defined as a mean log~2~ RPKM of 2.65 or higher. Only 29.8% of RNA-seq samples (*n* = 21,017) were above this expression cutoff. "Low" CSRnc transcription was defined as a mean log~2~ RPKM \< 2.65 (Figure [4A](#F4){ref-type="fig"}. Table [3](#T3){ref-type="table"}), which accounted for the remaining 32.7% of the samples (*n* = 23,074). The CSRnc transcription levels varied according to I~H~. Higher transcription (log~2~ RPKM), as well as, a more widespread transcription (proportion of samples) was found for I~μ~ in all datasets (Figure [S4](#SM1){ref-type="supplementary-material"}), supporting the current model of CSRnc transcription in which Iμ is constitutively active, and the other I~H~ are regulated according to particular microenvironmental signals.

###### 

General sequencing run metrics used for CSR-ncRNA expression analysis.

                     **log~2~RPKM**   **Samples**   **(%)**
  ------------------ ---------------- ------------- ---------
  Total              NA               70,603        100.0
  Highly expressed   \>2.65           21,017        29.8
  Low-expressed      \< 2.6\>0        23,074        32.1
  Not expressed      0                26,512        37.1
  Clustering set     \>0              44,091        62.9

![Quantitative analysis of CSRnc transcription using *recount2*. **(A)** Average log~2~-transformed RPKM distribution of the 10 I~H~ exons per sample. There were 44,091 samples with non-zero RPKM. Higher than the mean (log~2~RPKM \> 2.65) was considered "highly" transcribed (shown in red). "Low" CSRnc transcription was defined as a mean log~2~ RPKM \< 2.65 (green). **(B)** CSRnc transcription profiling by Z-score clustering. Log~2~RPKM CSRnc transcription values of GTEx + TCGA + SRA datasets were transformed to standardized Z-scores and subjected to *k*-means clustering with a predefined number of 10 clusters (*Left panel*). Clustered data is represented in a heatmap where I~H~\'s are columns and Z clusters are in rows. Negative Z-scores (i.e., \< 2.65 log~2~RPKM) are shown in green, positive Z-scores (i.e., \> 2.65 log~2~RPKM) are shown in red. Absent values (RPKM = 0) are shown in gray. Z values near 0 are shown in black. **(C)** Expression pattern of each cluster represented in boxplots. The Z-score distribution (y axis) per I~H~ (x axis) for each cluster of the 10 generated clusters. Dotted line indicates a Z-score = 0, which corresponds to the mean expression per sample (log2 RPKM = 2.65). Higher than the mean transcription is marked in red, whereas lower than the mean is marked in green.](fimmu-09-02679-g0004){#F4}

The *recount2* dataset is partitioned in distinctive CSRnc transcription profiles
---------------------------------------------------------------------------------

Cytokine milieu and other signals regulate CSR. To identify CSRnc transcriptional profiles that may result from different microenvironments, we further de-convoluted CSRnc transcription according to I~H~ relative transcription profile. To do so, the entire non-zero dataset including GTEx, TCGA, and SRA Z-scores was clustered in 10 groups using *k*-means clustering (Figures [4B,C](#F4){ref-type="fig"}). Using Z0 as reference, each of I~H~ showed a distinctive expression pattern in the remaining Z clusters (log~2~ RPKM regression analysis. F-statistic: *p*-value: \< 2.2e−16). Clusters Z0, Z2, and Z8 were characterized by low (mean log~2~ RPKM \< 2.65 or Z score \< 0) CSRnc transcription in all I~H~ classes. Clusters Z4, Z6, and Z7 were characterized by "high" expression of I~μ~ only (mean log~2~RPKM \> 2.65). Cluster Z3 showed "high" expression in I~μ~ and I~α2~. Cluster Z1 showed high expression in I~μ~, I~γ1~, and I~γ4~. Finally, clusters Z5 and Z9 showed "high" expression in all I~H~\'s (Figure [4C](#F4){ref-type="fig"}).

CSRnc transcription is widely distributed in healthy tissues, with particular profiles according to tissue
----------------------------------------------------------------------------------------------------------

To gain insight into CSRnc expression patterns in healthy adult human tissues, we used GTEx samples as a reference. Non-zero RPKM per tissue samples were ranked according to their average log~2~ RPKM. Higher average transcription was found in lymphoid tissues such as spleen, EBV-transformed B-lymphocytes and whole blood, but also in organs with mucosal-associated lymphoid tissues (MALT) such as terminal ileum, transverse colon, stomach, lung, and esophageal mucosa (Figure [5A](#F5){ref-type="fig"}). We observed a remarkable difference in average log~2~ RPKM between transverse colon (mean 7.5 ± 3.9) and sigmoid colon (mean 2.1 ± 3.2). Interestingly, salivary gland expression was among the tissues with highest transcription, and non-mucosal tissues such as thyroid and pituitary gland showed high average I~H~ transcription. Another notable difference in average log~2~ RPKM was between visceral adipose tissue (omentum; mean 4.9 ± 2.3) and subcutaneous adipose tissue (mean 1.9 ± 1.5). Conversely, samples of tissues such as brain, skeletal and cardiac muscle, skin, as well as, chronic myelogenous leukemia cell line K562 and transformed dermal fibroblast cell lines showed the lowest CSRnc transcription levels (mean log~2~ RPKM \< 2.65) (Figure [5A](#F5){ref-type="fig"}).

![CSRnc transcription in healthy adult tissues. **(A)** The GTEx dataset was partitioned according to tissue type. Violin plot of average log~2~RPKM distribution of GTEx project representative tissues, ordered form left to right according to each tissue median log~2~RPKM. The violin area was scaled according to sample count and median and quartiles are shown. A dotted black line marks the mean average log~2~RPKM (2.65). For simplicity, only brain cortex was included as a representative sample for central nervous system. **(B)** Regression analysis of CSRnc transcription as a function of tissue type and I-exon. Whole blood CSRnc transcription was used as reference tissue (*rows*) for regression analysis according to I-exon (*columns*). The estimate for each comparison is expressed as a heatmap. Higher CSRnc transcription than in blood is represented in blue tones, whereas lower transcription is shown in pink tones. Zero estimate values are shown in ivory. Missing values (NA\'s) are shown in white. Euclidian distance was used for hierarchical clustering by row. For simplicity, only representative tissues are shown.](fimmu-09-02679-g0005){#F5}

Using whole blood as reference tissue, we performed a linear regression analysis of each I~H~ by tissue type. The transcription pattern of each I~H~ in whole blood was significantly different (*p* \< 2.2e−16) (Figure [5B](#F5){ref-type="fig"}). I~μ~ transcription was similar to I~H~ average transcription (Figures [5A,B](#F5){ref-type="fig"}), in which we observed higher transcription in spleen, terminal ileum, salivary gland, and transverse colon than blood. Of note, I~μ~ transcription in testis was particularly low, despite its high average transcription. I~δ~ transcription was similar to I~μ~ transcription, but only spleen and terminal ileum were significantly higher. I~γ3~, I~γ1~, and I~γ2~ transcription was similar and was higher in spleen than in blood (*p* \< 2e−16) (Figure [5B)](#F5){ref-type="fig"}.

For most tissues we found high correlation between I~α1.1~ and I~α1.2~ transcription however, some differences were noted. I~α1.1~ transcription was higher in terminal ileum and transverse colon than in blood (*p* \< 0.001). In contrast, I~α1.2~ transcription was higher in spleen and salivary gland than in blood (*p* \< 2e−16). I~α1~ transcription was similar to I~α1.2~ transcription, but also was higher in stomach, esophageal mucosa than in blood (*p* \< 1.1e−05) (Figure [5B](#F5){ref-type="fig"}). Thus, I~α1~ and I~α2~ transcription pattern matches with the fact of IgA as the main immunoglobulin in mucosal tissue. Furthermore, our results suggest that CSR to IgA may involve tissue-dependent alternative transcription initiation and/or splicing in the corresponding CSRnc transcripts.

The most unexpected patterns of CSRnc transcription corresponded to I~γ4~ and I~ε~. Transcription for both was higher in spleen, terminal ileum and EBV-transformed B-cells than in blood (*p* \< 0.01). However, I~γ4~ transcription was higher in thyroid, visceral adipose tissue (omentum), testis, than in blood (*p* \< 2e−16). Similarly, I~ε~ transcription was higher in in thyroid than in blood (*p* \< 0.00003) (Figure [5B](#F5){ref-type="fig"}).

We tested if a particular CSRnc expression profile was associated to a particular tissue. Consistently with the regression analysis, de-convolution of CSRnc transcription according to I~H~ relative expression (Z-score) revealed that terminal ileum, spleen, transverse colon, whole blood and salivary gland share a similar expression pattern and are highly enriched (FDR \< 0.001) in clusters Z5 and Z9 (high transcription in all I~H~\'s) (Figure [6A](#F6){ref-type="fig"}). Some tissues with MALT such as stomach, esophageal mucosa and lung shared a similar I~H~ transcription pattern and were enriched in cluster Z5 and Z3 (high I~μ~ and I~α2~ transcription) (FDR \< 0.001), whereas others such as breast, vagina, liver were enriched in cluster Z3 and Z6 (I~μ~ only). Testis, thyroid, pituitary, and omentum, characterized by the highest I~γ4~ transcription, were enriched in cluster Z1 (I~μ~, I~γ1~, and high I~γ4~) (FDR \< 0.001). Finally, the remaining tissues such as subcutaneous adipose tissue, arteries, brain, skeletal, and cardiac muscle, skin, transformed fibroblasts and K562 cell lines, were enriched in Z0, Z2, and Z8 (low CSRnc transcription in all I~H~ classes) (FDR \< 0.001) (Figure [6A](#F6){ref-type="fig"}), and in few cases were enriched in clusters Z4 and Z6 (I~μ~ only) (FDR \< 0.001).

![CSRnc transcription profile variation in healthy tissue. **(A)** The GTEX dataset was categorized according to tissue (*x* axis) and the relative proportion of samples (y-axis) belonging to each Z cluster (in *colors*). Many central nervous system tissues with highly similar pattern were removed for simplicity. Proportions were hierarchically clustered using Pearson correlation as distance metric with Cluster3.0 ([@B18]). The red dotted line marks a correlation *R*^2^ = 0.7. The black asterisk indicates a significant enrichment of a given tissue in a particular Z cluster (Exact Fisher\'s test, Benjamini-Hochberg adjustment for multiple correction. FDR \< 0.01). **(B)** CSRnc (*rows, lower panel*) and C~H~ (*rows, upper panel*) transcription in B (*columns, left pane*l) and T cell precursors (*columns, right panel*). Z-score heatmap of I~H~ and C~H~ transcription in bone marrow from hematopoietic stem cells (HSC, CD34^+^CD38^−^lin^−^), lymphoid multipotent progenitors (LMPP, CD34^+^CD45RA^+^ CD38^+^CD10^−^CD62L^hi^lin^−)^, common lymphoid progenitors (CLP, CD34^+^CD38^+^CD10^+^CD45RA^+^lin^−^), and committed B cell progenitors (BCP, CD34^+^,CD38^+^,CD19^+^) are shown in the left panel. CSRnc and C~H~ transcription in thymic lymphoid precursors in thymic early lymphoid precursors with myeloid potential Thy1 (CD34^+^CD7^−^ CD1a^−^ CD4^−^CD8^−^) and Thy2 (CD34^+^CD7^+^CD1a^−^ CD4^−^CD8^−^), as well as, fully committed T cell precursors Thy3 (CD34^+^CD7^+^CD1a^+^CD4^−^ CD8^−^), Thy4 (CD4^+^CD8^+^), Thy5 (CD3^+^CD4^+^CD8^−^), and Thy6 (CD3^+^CD4^−^ CD8^+^). Data was obtained from study SRP058719 ([@B40]). Each value represents the mean ± SD of two biological replicates. **(C)** CSRnc I~H~ and C~H~ transcription in fetal tissues from study SRP055513 ([@B41]). Heatmap of Z-score average per tissue (*n* = 3--8) of I~H~ and C~H~ (*rows*) in 9--22 weeks of gestation fetal tissues (*columns*). Higher transcription (Z-scores) are shown in green-yellow, lower expression and no expression is shown in purple and gray, respectively. Higher than average expression of I~γ4~ is observed in all tested tissues. Z-score color code as in **(B)**.](fimmu-09-02679-g0006){#F6}

The observed anatomical distribution and abundance of CSRnc transcription suggests that the amount of CSRnc transcription may be dependent on the abundance of B cells present in a given tissue. We used the C~H~ coding transcript log~2~RPKM as a proxy of the amount of B cells in the tissue. In general, C~H~ transcription was 10--100-fold higher than CSRnc transcription. To correlate CSRnc transcription with corresponding C~H~ transcription, Z-scores were used. As expected for each class, CSRnc and C~H~ Z-scores where significantly correlated (*p* \< 1.0e−16), suggesting that the higher numbers of B cells or plasma cells in a given tissue, higher CSRnc transcription. However, we have noticed that for most classes, a fraction of samples deviates from the expected orthogonal correlation, indicating higher CSRnc transcription relative to the C~H~ transcript. This is particularly notable for I~μ~, but also, I~γ1~, I~γ4~, and I~α2~ (Figure [S5](#SM1){ref-type="supplementary-material"}). We suggest that this higher relative expression of I~H~ regarding C~H~ indicates active CSR.

Iμ transcription occurs in early lymphoid progenitors and i~γ4~ is widely expressed in non-lymphoid fetal tissues
-----------------------------------------------------------------------------------------------------------------

CSRnc transcription was addressed in early lymphoid development using data from study SRP058719, which addresses transcription in early lymphoid differentiation prior to and after B and T cell lineage commitment using RNA-seq from FACSorted cells ([@B40]). Interestingly, both B and T lineage precursors expressed I~μ~. Enriched hematopoietic stem cells (HSC\'s CD34^+^CD38^−^lin^−^), lymphoid-primed multipotent progenitors (LMPP\'s, CD34^+^CD38^+^CD10^−^ CD45RA^+^lin^−^), common lymphoid progenitors (CLP\'s, CD34^+^CD38^+^CD10^+^CD45RA^+^lin^−^), thymic CD34^+^CD7^−^ CD1a^−^ CD4^−^CD8^−^ (Thy1) precursors and fully B cell-committed progenitors (BCPs, CD34^+^CD38^+^CD19^+^) expressed Iμ (Figures [6B](#F6){ref-type="fig"}).

We analyzed CSRnc expression in fetal tissue by using project SRP055513 data, which reported an extensive RNA-seq analysis in twenty fetal tissues during gestational weeks 9--22 ([@B41]). Remarkably, we detected a robust I~γ4~, but not IGHG4 expression in all fetal tissues tested, regardless of the gestational week (Figure [6C](#F6){ref-type="fig"}). Higher average I~γ4~ expression is in spleen, followed by lung and liver. The latter has lympho-hematopoietic function in the fetal stage. In contrast with their adult counterparts, I~γ4~ was highly transcribed (Z-score \> 0.8) in kidney, brain and muscle.

CSRnc transcription in cancer varies according to cancer type and is likely to depend on the degree of B cell tumor infiltration
--------------------------------------------------------------------------------------------------------------------------------

The TCGA project data was used as a reference to study CSRnc transcription in a wide variety of human cancers. As for GTEx, we analyzed CSRnc transcription (I~H~ average log~2~ RPKM distribution) across 33 cancer types (Figure [7](#F7){ref-type="fig"}). I~H~ transcription in diffuse large B cell lymphoma (DLBCL) and acute myeloid leukemia (AML) were the highest. In general, CSRnc transcription in neoplastic tissue mimicked its non-neoplastic counterparts, being high in lung, stomach, and testicular germ cell carcinomas. Conversely, CSRnc transcription was low in glial cell and skin cancers (Figure [7](#F7){ref-type="fig"}).

![CSRnc transcription in cancer. RNA-seq data from the TCGA project was used to analyze CSRnc transcription in 33 cancer types. Violin plots of average log~2~RPKM, ordered from left to right according to increasing median. Violin area is scaled to each tumor sample count. A dotted black line marks the average log~2~RPKM = 2.65.](fimmu-09-02679-g0007){#F7}

A direct comparison between CSRnc transcription in healthy (GTEx) and neoplastic tissue allowed the identification of three distinct patterns (Figure [8](#F8){ref-type="fig"}): (**1)** Tumors where average CSRnc transcription is lower than in healthy tissue, such as in DLBCL, prostate, thyroid, liver, and colon cancer (Figures [8A--E](#F8){ref-type="fig"}). (**2)** Tumors where average CSRnc transcription was higher than its healthy tissue counterpart, such as breast, rectum, testicular germ cell, pancreas carcinomas, ovarian cystadenoma, and skin melanoma (Figure [8G--L](#F8){ref-type="fig"}). (**3)** Tumors with no difference in CSRnc transcription between healthy and neoplastic counterpart, such as stomach and esophagus (Figure [S6](#SM1){ref-type="supplementary-material"}). Interestingly, using healthy kidney cortex as reference for kidney tumors, CSRnc transcription varied according to cancer type, CSRnc transcription was significantly lower in chromophobe and papillary carcinomas, but not in clear cell carcinoma. (Figure [8F](#F8){ref-type="fig"}). In adrenal gland, we observed a similar pattern, with lower CSRnc transcription in adrenocortical carcinoma, but not pheochromocytoma (Figure [S6](#SM1){ref-type="supplementary-material"}).

![Comparison of CSRnc transcription in healthy tissue and its tumoral counterpart. Violin plots of the average log~2~RPKM distribution in healthy tissue (*blue*) in comparison with its cancer tissue counterpart (*purple*). Violin area are not scaled to sample count. Median (*black dot*) and quartiles are shown for each violin. Dashed black line marks the mean average log~2~RPKM (2.65). A reduction of CSRnc transcription in tumors was observed in **(A--E)**. An increase of CSRnc transcription in tumors vs. healthy tissue was observed in **(G--K)**. Some types of kidney cancers and melanomas showed an opposite patterns regarding the healthy tissue counterpart **(F,L)**. The conducted statistical test were Wilcoxon rank sum test with continuity correction for two-sample comparisons, and Kruskal-Wallis test with *post hoc* Dunn\'s test correction for multiple comparisons.](fimmu-09-02679-g0008){#F8}

The correlation between CSRnc and C~H~ transcription (Figure [S5](#SM1){ref-type="supplementary-material"}) suggests that as for healthy tissues, CSRnc transcription derives from tertiary lymphoid infiltrates resulting from tumor-associated inflammation and the corresponding mucosal associated lymphoid tissues ([@B42]). To address this question, we analyzed CSRnc transcription in a wide variety of tumor-derived cell lines in SRA. The majority of the representative tumor derived cell lines tested (i.e., lung cancer A549 cells, breast cancer MCF-7 cells, and colon cancer HCT116 cells) were depleted in samples expressing CSRnc RNA (Table [S2](#SM2){ref-type="supplementary-material"}), indicating that CSRnc transcription in cancer derives from infiltrating B cells, and not the neoplastic cells *per se*. Nevertheless, using this approach, CSRnc transcription in cancer cells *in situ* cannot be ruled out.

CSRnc transcription is altered in certain infectious conditions and a i~δ~-i~α2~ transcriptional signature is associated with pediatric crohn\'s disease with deep ulceration
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The SRA dataset represents the most diverse collection of data regarding methodological approaches and subjects of interest and represents a useful source of data related to diverse malignancies, as well as, infectious and non-infectious inflammatory pathology. Using MetaSRA Disease Ontology annotations ([@B16]), we identified significant enrichment of acute AML, breast, and lung cancers in SRA samples with CRSnc transcription, confirming our observations derived from TCGA data analysis.

Moreover, the SRA dataset allowed us to identify enriched CSRnc expression in infectious diseases such as diarrhea, brucellosis, and malaria. However, in all cases, peripheral blood samples were used for these experiments. To distinguish if the enrichment was due to increased expression, rather than for the inherent enrichment observed in blood (Figure [5](#F5){ref-type="fig"}), we performed differential expression analysis comparing experimental groups provided by SRA metadata. We detected significant reduction of CSRnc transcription in enterobacteria, but not in rotavirus diarrheal disease (SRP059039), malaria (SRP032775) ([@B43]), brucellosis and leishmaniasis (SRP059172) (Table [S3](#SM2){ref-type="supplementary-material"}). SRA data from influenza vaccination (SRP020491) ([@B28]) was consistent with our own experimental data demonstrating no significant changes in CSRnc transcription 7 days post-vaccination, regardless the plasmablast migration wave to peripheral blood at that time, indicating that CSRnc transcripts observed in peripheral blood do not derive from recently class-switched plasmablasts (Figures [3L--O](#F3){ref-type="fig"}). CSRnc transcription in response to influenza vaccination contrasted with the observation that natural infection with H7N9 ([@B44]) (SRP033696), in which we observed changes in coding and CSRnc transcription (Table [S3](#SM2){ref-type="supplementary-material"}).

The SRA dataset also showed enrichment for autoimmune disease terms such as systemic lupus erythematous and autoinflammatory diseases like inflammatory bowel disease. No significant differential expression was observed in peripheral blood transcriptomes in systemic lupus erythematosus patients compared with healthy subjects (SRP062966) ([@B45]) (Table [S3](#SM1){ref-type="supplementary-material"}). However, a study comparing the ileal transcriptome in pediatric Crohn\'s disease (CD) with and without deep ulceration, and with or without ileal involvement (SRP042228) ([@B46]), revealed an increased significant expression for I~μ~, I~δ~, and I~α2~ in patients with deep ulcerated CD, regardless the presence of macroscopic or microscopic inflammation (Figure [9](#F9){ref-type="fig"} and Table [S3](#SM2){ref-type="supplementary-material"}).

![Increased I~δ~ transcription in ileal mucosa of Crohn\'s disease. Pediatric Crohn\'s disease patients from project SRP042228 were classified in two groups according to ileal mucosa involvement (iCD) on non-involvement (cCD) ([@B46]). Patients were further classified according to the degree of ileal mucosa inflammation. Ileal mucosa from non-inflammatory bowel disease (nIBD) and ulcerative colitis (UC) were used as controls ([@B46]). **(A)** Boxplot showing increased Iδ transcription (RPKM, *y axis*) in deep ulcerated Crohn\'s disease with ileal involvement (one factor ANOVA, Tukey multiple comparisons of means. *P* \< 0.005). **(B)** Transcriptional landscape of the *IGHD*-*IGHM* locus in human chromosome 14 showing increased I~δ~ transcription in representative samples of deep ulcerated ileal involved CD (iCD, *red track*), CD with microscopic inflammation (cCD, *blue track*), iCD with macroscopic inflammation (*purple track*), non- inflammatory bowel disease (IBD, *black track*) and ulcerative colitis (UC, *orange track*).](fimmu-09-02679-g0009){#F9}

Discussion {#s4}
==========

We performed an integral, systematic analysis of human CSRnc transcription using an experimental approach and datamining of a large and diverse public RNA-seq dataset supported by a previously described resource, *recount2* ([@B12]). The precise I-exon boundaries for every class were undefined and are not annotated in current human genome version (GRCh38.p12). Among hematopoietic-derived cells, CSRnc transcription was specific for B cells, and consistent with previous findings was present in naïve, as well as, GC-B cells ([@B5]).

The present study has certain limitations. CSRnc transcription is required for CSR, however it does not prove that CSR is actively taking place. Among the most determinant factors influencing the amount of CSRnc transcription observed in an RNA-seq sample is the relative amount of B cells expressing a particular I-exon, as suggested by the high Z-score correlation between CSRnc and its corresponding C~H~ transcript (Figure [S5](#SM1){ref-type="supplementary-material"}). We propose that the higher non-coding/coding Z-score ratio indicates a higher proportion of B cells undergoing a particular CSR event. Other factors influencing the amount of CSRnc transcription is that switch circles are transcriptionally active ([@B47]), and our current analysis cannot differentiate if CSRnc transcripts derive from chromosomal or switch circle transcription. Switch circles are non-replicating episomes that decay with B cell division ([@B48]--[@B50]). Thus, B cells undergoing cell division at high rate (i.e., GC B cells) should dilute the amount of circle templates in a greater extent than non-dividing B cells.

A novel transcribed element (I~δ~) located in the *IGHM*-*IGHD* intergenic region was identified, which overlaps with a previously described repeat Σ~μ~ region, downstream of an atypical switch region (σδ) involved in non-classical CSR to IgD in mice ([@B51]) and humans ([@B21]--[@B23]). The Σμ region was originally described as mediator of μ-δ CSR by homologous recombination in myeloma cell lines ([@B20], [@B24]). The biological role of Σμ is uncertain, because IgD^+^ EBV-transformed cell lines and human tonsillar B cells undergo μ-δ CSR by non-homologous recombination using σδ as acceptor switch region ([@B21], [@B22]), in an AID-dependent fashion ([@B23]). Here, we demonstrate that I~δ~ (Σμ) can be actively transcribed (Figure [1C](#F1){ref-type="fig"}). Nonetheless, I~δ~ as an acceptor I-exon does not fit into the general model of CSR, because it is located downstream of the σδ region. Further research is required to elucidate if I~δ~ transcription is involved in the non-classical μ-δ CSR.

An important motivation for this work was the identification of early transcriptional signatures in blood that correlated with the strength and quality of the humoral response, and in particular with the GC response. Interestingly, Hepatitis B and or Tetanus/Diphteria vaccination induced I~μ~, and I~γ3~ transcription in peripheral blood at day 14 post-vaccination, but not when plasmablasts peaked (day 7 post-vaccination), suggesting that CSRnc transcription may not be the result of plasmablast mobilization to peripheral blood. Moreover, we observed increased I~γ1~ and I~α1~ transcription in natural H7N9 infection, but not upon influenza vaccination (Figure [3](#F3){ref-type="fig"}, Table [S3](#SM1){ref-type="supplementary-material"}), or in rotavirus infection (Table [S3](#SM1){ref-type="supplementary-material"}). The differential response observed upon influenza vaccination and natural rotavirus infection in contrast to HBV/tetanus-diphteria vaccination and H7N9 infection may be the result of the common repeated exposure to seasonal influenza or rotavirus, which would reactivate IgG^+^ memory B cells and in the absence of CSR ([@B52]).

Although I~H~ transcription is highly inducible upon activation (Figure [3A-D](#F3){ref-type="fig"}), GTEx and SRA mining revealed that I~μ~ transcription was higher than other I~H~. This is consistent with the current model of CSR, in which I~μ~ is constitutively transcribed under the control of the μ intronic enhancer (E~μ~), and its transcription is required for CSR regardless of the acceptor class ([@B53]). E~μ~ participates in chromatin remodeling of the IgH locus during lineage commitment and VDJ recombination ([@B54], [@B55]), and its deletion impairs B cell development, I~μ~ transcription and CSR ([@B56]).

We identified distinctive CSRnc transcriptional patterns related to known immunological functions, such as I~μ~ and I~α2~ co-expression in MALT-rich organs, where active IgA secretion takes place. Of particular interest is cluster Z1, defined by an I~γ1~, I~γ2~, and I~γ4~ transcriptional signature. Z1 cluster was the only cluster with higher expression of I~γ4~, and was characteristic of the testis, thyroid gland and visceral adipose tissue (omentum), but not subcutaneous adipose tissue. Visceral adipose lymphoid B cells are immunologically active cells implicated in adipose tissue homeostasis that may play important pro-inflammatory roles associated with metabolic syndrome and obesity ([@B57]). The expression of I~γ1~ and I~γ4~ transcriptional signature in testis and thyroid is unexpected, because they are regarded as immune-privileged sites devoid of secondary/tertiary lymphoid organs ([@B58]). Similarly, higher I~ε~ transcription in the thyroid gland is a striking finding worthy of further research due to the common association of atopic disease with autoimmune thyroiditis ([@B59]). At present, we do not know if CSR to IgG~4~ or IgE is taking place, however further research is required given that IgG~4~ is an atypical Ig that lacks Fc-mediated effector functions ([@B60]) and IgE could be implicated in autoimmunity. Furthermore, I~γ4~ transcription in different fetal tissues suggests that its transcription is not limited to lymphoid tissue, may be a common feature of multipotency and is not necessarily coupled with C~H~ transcription, suggesting additional functions beyond CSR.

A major goal of the GTEx project was to identify the role of genetic variation in gene expression as a quantitative trait. Tissue enrichment in two clusters with qualitatively different I~H~ transcriptional pattern such as in liver (Z3 and Z6), testis (Z1 and Z2), terminal ileum (Z5 and Z9), and whole blood (Z5, Z7, and Z9) indicate CSRnc transcriptional heterogeneity in tissue donors involved in the GTEx project. This could result from different tissue microenvironments (i.e., cytokine/chemokine milieu, microbiota and environmental stimuli), as well as, genetics, which may modify CSRnc transcription patterns and possibly CSR itself. A recent study identified four SNP\'s in the human IgH locus presumably involved in CSR that affect immunoglobulin levels ([@B61]). Their implication in modifying CSRnc transcription warrants further investigation.

The study of CSRnc transcription in cancer is of particular interest for several reasons: (**1**) The anti-tumor response is largely mediated by the presentation of tumor neo-antigens to T cells and T~reg~ balance. However, antibody-mediated anti-tumor activity can be achieved by antibody---dependent cytotoxicity or other mechanisms ([@B42]). (**2**) The presence of ectopic (or tertiary) lymphoid structures (ELS) ([@B42], [@B62]) and higher densities of infiltrating B cells and T follicular helper cells correlate with improved survival in lung ([@B63]), breast ([@B64]), and colorectal carcinoma ([@B65]). (**3**) The tumor microenvironment, including certain cytokines may modify CSR patterns in infiltrating and ELS B cells, regardless the antibody effector function. (**4**) AID activity is a known contributor to off-target mutagenesis and genomic instability in B cell malignancies ([@B66]). Aberrant AID and CSRnc transcription in non-lymphoid tumor cells could potentially contribute to cytidine deaminases---mediated kataegis ([@B67]).

We have found that average I~H~ expression in certain tumors analyzed in the TCGA project resembles their non-neoplastic counterpart; however, some cancer types have significantly less CSRnc transcription, whereas others show the opposite. Most of the evidence we have gathered so far indicate that the origin of I~H~ transcription is in the tumor infiltrating and ELS B cells, rather than the tumor cells *per se* (Table [S2](#SM2){ref-type="supplementary-material"}). Thus, differences in I~H~ transcription in cancer may be the result of immune editing ([@B68]), which may alter the amount and activation state of the infiltrating and ELS B cells. Based on gene expression signature clustering, all non-hematologic cancers of the TCGA project were classified into six immunologically distinct subtypes with distinctive somatic aberration patterns, tumor microenvironment including the amount and cell type infiltration, and clinical outcome ([@B69], [@B70]). The relation between these six immunological subtypes with CSRnc transcription pattern may help to understand the elusive role of infiltrating B cells in the progression of different cancer types ([@B42]).

Despite the limitation of relying on public data when often the submitter researcher chooses to submit the minimal requirements of sample metadata, the SRA represents an enormous source of RNA-seq data from a highly diverse type of studies. In contrast to the standardized methodological criteria and metadata collection protocols used by the GTEx and TCGA consortiums, higher methodological variability in SRA data is expected, limiting inter-study comparisons. Nevertheless, we were able to identify a I~μ~- I~δ~, - I~α2~ signature in ileal mucosa of Crohn\'s disease in a treatment-naive pediatric cohort ([@B46]). I~μ~ and I~α2~ is somehow expected as the result of predominant IgM to IgA CSR on mucosal tissue (Figures [4B--C](#F4){ref-type="fig"}, [5B](#F5){ref-type="fig"}, [6A](#F6){ref-type="fig"}), and its exacerbation due to increased tissue B cell infiltration in response to inflammation ([@B46]). However, the increased I~δ~ transcription, particularly in CD associated with deep ulceration is an intriguing finding (Figure [9](#F9){ref-type="fig"}). Serum IgD levels are elevated in patients with CD ([@B71]) and other autoinflammatory syndromes ([@B23], [@B72]). A high proportion of μ-δ switched IgD^+^ cells bare autoreactive and poly-reactive specificities ([@B73], [@B74]), a feature shared with "natural autoantibodies," which are reactive against bacterial wall components and may provide natural immunity against bacterial infection ([@B75]). In human respiratory mucosa, μ-δ switched IgD^+^ B cells mediate the innate-adaptive immunity and inflammatory cross talk ([@B23]). Mice incapable of undergoing classic CSR due loss of function of 53BP1 have an intestinal microbiota-dependent elevation of IgD serum titers and increased μ-δ switched IgD^+^ B cells ([@B76]). Direct experimental testing is required to elucidate the role of I~δ~ transcription, its role in μ-δ CSR and its implications in healthy and inflamed mucosae.

In conclusion, we have performed an unbiased analysis of the transcriptional landscape of the human *IGH* locus using a vast public RNA-seq dataset. Our observations agree with previous findings regarding constitutive CSRnc transcription in naïve B cells and its upregulation upon activation. We provide a detailed analysis of CSRnc transcription in healthy tissue. As expected, CSRnc transcription correlated with the amount of associated lymphoid tissue, however, we found novel transcriptional signatures involving I~γ4~ or I~ε~ in testis, pituitary, thyroid, and visceral adipose tissue. Changes in CSRnc transcription between healthy and tumor tissue were also found, likely as a result of immune editing. A novel transcribed element within the *IGHM-IGHD* intron termed I~δ~ was discovered and highly expressed in ileal mucosae of pediatric Crohn\' s disease patients. Overall, this study highlights the importance of open access data for discovery and generation of novel hypothesis amenable for direct testing, and is a great example of the potential of the *recount2* dataset to further our understanding of transcription, including regions outside the known transcriptome.
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AID

:   Activated-Induced Cytidine Deaminase

CD

:   Crohn\'s disease

CSRnc

:   Class Switch Recombination non-coding

CSR

:   Class Switch Recombination

CG

:   Germinal Center

C~H~

:   Heavy chain Constant

ELS

:   Ectopic Lymphoid Structures

EBV

:   Epstein Barr Virus

GTEx

:   Genotype-Tissue Expression Project

I~H~

:   I exon

MALT

:   Mucosal Associated lymphoid Tissue

PAMP

:   Pathogen-Associated Molecular Pattern

PB

:   Peripheral blood

SRA

:   Sequence Read Archive

RPKM

:   Reads Per Kilobase (transcript) Per Million (reads)

TCGA

:   The Cancer Genome Atlas.
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